Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

PLoS One · 2014 · PMC4077767 · PMID 24983357

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a possible trendp>0.05actually significant

( E ) Excluding an outlier from the linear regression shows a possible trend emerging for BIM where higher levels of mRNA expression might be positively associated with duration of treatment (p>0.05).

also in 1,410 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.